• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.两种剂量水平哌拉西林的群体药代动力学:非线性药代动力学对药效学特征的影响。
Antimicrob Agents Chemother. 2012 Nov;56(11):5715-23. doi: 10.1128/AAC.00937-12. Epub 2012 Aug 20.
2
Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.重症患儿中延长输注哌拉西林和他唑巴坦的群体药代动力学和药效学
Antimicrob Agents Chemother. 2015 Nov 9;60(1):522-31. doi: 10.1128/AAC.02089-15. Print 2016 Jan.
3
Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.哌拉西林在健康志愿者中的非线性药代动力学——对最佳剂量方案的影响。
Br J Clin Pharmacol. 2010 Nov;70(5):682-93. doi: 10.1111/j.1365-2125.2010.03750.x.
4
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.医院获得性感染住院患者哌拉西林他唑巴坦延长输注的群体药代动力学。
Antimicrob Agents Chemother. 2012 Aug;56(8):4087-94. doi: 10.1128/AAC.00521-12. Epub 2012 May 14.
5
Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.危重症患者行连续性肾脏替代治疗时哌拉西林他唑巴坦的群体药代动力学:在药代动力学/药效学分析中的应用。
J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1.
6
Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.哌拉西林/他唑巴坦延长输注在成人囊性纤维化相关急性肺部感染中的药代动力学和药效学。
J Antimicrob Chemother. 2014 Jan;69(1):176-9. doi: 10.1093/jac/dkt300. Epub 2013 Jul 18.
7
Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.肥胖和非肥胖患者长时间输注哌拉西林和他唑巴坦的群体药代动力学和药效学
J Clin Pharmacol. 2015 Aug;55(8):899-908. doi: 10.1002/jcph.505. Epub 2015 May 13.
8
Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.哌拉西林/他唑巴坦在新生儿和小婴儿群体药代动力学研究中的目标达成分析及最优抽样设计
Eur J Clin Pharmacol. 2016 Dec;72(12):1479-1488. doi: 10.1007/s00228-016-2131-0. Epub 2016 Sep 19.
9
Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?哌拉西林在感染性休克早期的群体药代动力学:标准剂量能否达到治疗性血浆浓度?
Antimicrob Agents Chemother. 2015 Nov;59(11):7018-26. doi: 10.1128/AAC.01347-15. Epub 2015 Sep 8.
10
Dose optimization of piperacillin/tazobactam in critically ill children.哌拉西林/他唑巴坦在危重症儿童中的剂量优化。
J Antimicrob Chemother. 2017 Jul 1;72(7):2002-2011. doi: 10.1093/jac/dkx093.

引用本文的文献

1
A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly.哌拉西林/他唑巴坦在不同患者群体中的汇总药代动力学分析:从早产儿到老年人。
Clin Pharmacokinet. 2025 Jan;64(1):107-126. doi: 10.1007/s40262-024-01460-6. Epub 2024 Dec 25.
2
Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing .平衡天平:连续输注哌拉西林/他唑巴坦对抗产超广谱β-内酰胺酶的. ,实现最佳β-内酰胺与β-内酰胺酶抑制剂比值。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0140423. doi: 10.1128/aac.01404-23. Epub 2024 Feb 27.
3
Individualized antibiotic dosage regimens for patients with augmented renal clearance.针对肾脏清除率增加患者的个体化抗生素给药方案。
Front Pharmacol. 2023 Jul 26;14:1137975. doi: 10.3389/fphar.2023.1137975. eCollection 2023.
4
Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients.重症患者持续输注哌拉西林后的暴露预测因素及其对目标达成情况的影响
Antibiotics (Basel). 2023 Mar 7;12(3):531. doi: 10.3390/antibiotics12030531.
5
Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.哌拉西林/他唑巴坦在成人全生命周期的群体药代动力学。
Clin Pharmacokinet. 2023 Jan;62(1):127-139. doi: 10.1007/s40262-022-01198-z. Epub 2023 Jan 12.
6
Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn.哌拉西林和他唑巴坦在创伤或烧伤重症患者中的药代动力学比较
Antibiotics (Basel). 2022 May 4;11(5):618. doi: 10.3390/antibiotics11050618.
7
Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients.利用经验证的群体药代动力学模型为危重症成年患者推荐持续输注哌拉西林的剂量。
Clin Pharmacokinet. 2022 Jun;61(6):895-906. doi: 10.1007/s40262-022-01118-1. Epub 2022 Mar 28.
8
Personalized Antibiotic Therapy for the Critically Ill: Implementation Strategies and Effects on Clinical Outcome of Piperacillin Therapeutic Drug Monitoring-A Descriptive Retrospective Analysis.危重症患者的个体化抗生素治疗:哌拉西林治疗药物监测的实施策略及其对临床结局的影响——一项描述性回顾性分析
Antibiotics (Basel). 2021 Nov 26;10(12):1452. doi: 10.3390/antibiotics10121452.
9
Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.儿童连续肾脏替代治疗中常用药物的药代动力学:当前文献的系统评价。
Clin Pharmacokinet. 2022 Feb;61(2):189-229. doi: 10.1007/s40262-021-01085-z. Epub 2021 Nov 30.
10
Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.哌拉西林-他唑巴坦在重症监护病房中的应用:群体药代动力学分析综述。
Clin Pharmacokinet. 2021 Jul;60(7):855-875. doi: 10.1007/s40262-021-01013-1. Epub 2021 Apr 20.

本文引用的文献

1
Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.药物动力学和药效学建模与危重症患者临床治疗的相关性。
Curr Pharm Biotechnol. 2011 Dec;12(12):2044-61. doi: 10.2174/138920111798808428.
2
Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.囊性纤维化患者和健康志愿者中头孢吡肟的群体药代动力学和药效学相似的折点。
Antimicrob Agents Chemother. 2011 Jun;55(6):2927-36. doi: 10.1128/AAC.01484-10. Epub 2011 Mar 14.
3
Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.运用并行 S-ADAPT 的蒙特卡罗重要性抽样算法在基本和复杂机械模型中的性能和稳健性。
AAPS J. 2011 Jun;13(2):212-26. doi: 10.1208/s12248-011-9258-9. Epub 2011 Mar 4.
4
Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.开发一个新的 S-ADAPT 中非线性混合效应建模的预处理和后处理工具(SADAPT-TRAN)。
AAPS J. 2011 Jun;13(2):201-11. doi: 10.1208/s12248-011-9257-x. Epub 2011 Mar 3.
5
Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.哌拉西林在健康志愿者中的非线性药代动力学——对最佳剂量方案的影响。
Br J Clin Pharmacol. 2010 Nov;70(5):682-93. doi: 10.1111/j.1365-2125.2010.03750.x.
6
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.丙磺舒对环丙沙星及其代谢物在肾小管分泌的竞争抑制作用。
Br J Clin Pharmacol. 2010 Feb;69(2):167-78. doi: 10.1111/j.1365-2125.2009.03564.x.
7
First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.危重症脓毒症患者连续或间断给药时哌拉西林的首剂和稳态群体药代动力学和药效学。
Int J Antimicrob Agents. 2010 Feb;35(2):156-63. doi: 10.1016/j.ijantimicag.2009.10.008. Epub 2009 Dec 16.
8
Augmented renal clearance: implications for antibacterial dosing in the critically ill.增强的肾功能清除:对危重症患者抗菌药物剂量的影响。
Clin Pharmacokinet. 2010;49(1):1-16. doi: 10.2165/11318140-000000000-00000.
9
Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.丙磺舒对吉米沙星肾小管分泌的竞争性抑制作用。
Antimicrob Agents Chemother. 2009 Sep;53(9):3902-7. doi: 10.1128/AAC.01200-08. Epub 2009 Jun 29.
10
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.抗菌治疗的药代动力学-药效学:不再只是针对小鼠了。
Clin Infect Dis. 2007 Jan 1;44(1):79-86. doi: 10.1086/510079. Epub 2006 Nov 27.

两种剂量水平哌拉西林的群体药代动力学:非线性药代动力学对药效学特征的影响。

Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

机构信息

IBMP - Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.

出版信息

Antimicrob Agents Chemother. 2012 Nov;56(11):5715-23. doi: 10.1128/AAC.00937-12. Epub 2012 Aug 20.

DOI:10.1128/AAC.00937-12
PMID:22908169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3486597/
Abstract

Piperacillin in combination with tazobactam is one of the most commonly used intravenous antibiotics. There is evidence for a possible saturable elimination of piperacillin. Therefore, the saturable elimination and its impact on the choice of optimal dosage regimens were quantified. In a randomized crossover study, 10 healthy volunteers received 1,500 mg and 3,000 mg of piperacillin as 5-min intravenous infusion. Population pharmacokinetics based on plasma and urine data were determined utilizing NONMEM and S-ADAPT. Probabilities of target attainment (PTAs) were compared for different models and dosage regimens, based on the target time of the non-protein-bound concentration above the MIC of at least 50% of the dosing interval. Total clearance of piperacillin was 18% (geometric mean ratio, 90% confidence interval, 11 to 24%) lower (P < 0.01), and renal clearance was 24% (9 to 37%) lower (P = 0.02) at the high compared to the low dose. The final model included first-order nonrenal elimination and parallel first-order and mixed-order renal elimination. Nonrenal clearance was 5.44 liter/h (coefficient of variation, 18%), first-order renal clearance was 4.42 liter/h (47%), and the maximum elimination rate of mixed-order renal elimination was 219 mg/h (84%), with a Michaelis-Menten constant of 36.1 mg/liter (112%). Compared to models with saturable elimination, a linear model predicted up to 10% lower population PTAs for high-dose short-term infusions (6 g every 8 h) and up to 4% higher population PTAs for low-dose continuous infusions (6 g/day). While renal elimination of piperacillin was saturable at therapeutic concentrations, the extent of saturation of nonrenal clearance was small. The influence of saturable elimination on PTAs for clinically relevant dosage regimens was relatively small.

摘要

哌拉西林他唑巴坦是最常用的静脉用抗生素之一。有证据表明哌拉西林可能存在饱和消除。因此,本研究旨在定量评估哌拉西林的饱和消除及其对最佳剂量方案选择的影响。在一项随机交叉研究中,10 名健康志愿者接受了 1500mg 和 3000mg 的哌拉西林,以 5 分钟静脉输注。利用 NONMEM 和 S-ADAPT 基于血浆和尿液数据确定群体药代动力学。基于非蛋白结合浓度在 MIC 以上的时间达到目标的 50%以上的目标时间,比较了不同模型和剂量方案的目标浓度达标概率(PTAs)。与低剂量相比,高剂量时哌拉西林总清除率降低 18%(几何均数比,90%置信区间为 11%至 24%)(P < 0.01),肾清除率降低 24%(9%至 37%)(P = 0.02)。最终模型包括一级非肾消除和平行一级和混合级肾消除。非肾清除率为 5.44 升/小时(变异系数 18%),一级肾清除率为 4.42 升/小时(47%),混合级肾消除的最大消除率为 219 毫克/小时(84%),米氏常数为 36.1 毫克/升(112%)。与饱和消除模型相比,线性模型预测高剂量短期输注(每 8 小时 6g)的群体 PTA 低 10%,低剂量连续输注(6g/天)的群体 PTA 高 4%。虽然哌拉西林的肾消除在治疗浓度下呈饱和状态,但非肾清除的饱和程度较小。饱和消除对临床相关剂量方案的 PTA 的影响相对较小。